Luay Abu-Qatouseh | Drug Safety and Risk Management | Research Excellence Award Published on 15/04/202615/04/2026 by Top Pharmaceutical After Completing the Registration Process, your Biography will be displayed here. Register by using your Entry ID: 2637 Register Here
Evgeni Grigorov | Pharmacovigilance | OncologyPharmaOnc Trailblazer Award Published on 15/04/202615/04/2026 by Top Pharmaceutical After Completing the Registration Process, your Biography will be displayed here. Register by using your Entry ID: 2636 Register Here
Palma Rocchi | Nanomedicine | Research Excellence Award Published on 09/04/202609/04/2026 by Top Pharmaceutical Prof. Dr. Palma Rocchi | Nanomedicine | Research Excellence Award Director | Aix-Marseille University | France Prof. Dr. Palma Rocchi is a distinguished professor at Aix-Marseille University, France, specializing in biomedical and cancer research. She holds advanced degrees in life sciences with a focus on molecular and cellular biology, forming a strong academic foundation for her scientific career. Her professional experience includes leading multidisciplinary research teams, contributing to innovative projects, and playing key roles in academic and institutional development. Her research primarily focuses on cancer biology, therapeutic targets, and translational medicine, with a substantial body of highly cited publications demonstrating significant contributions to scientific advancement. She has been actively involved in editorial responsibilities, peer review activities, and international research collaborations, reflecting her leadership within the scientific community. Her achievements have been recognized through multiple awards and honors, along with memberships in prominent scientific organizations, highlighting her commitment to excellence, innovation, and impactful research in her field. Citation Metrics (Google Scholar) 8760 6000 3000 1000 0 8760 77 49 Citations i10-index h-index View Scopus Profile View Google Scholar Profile Top 5 Featured Publications Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development – PNAS, 2007 Coronavirus RNA proofreading: molecular basis and therapeutic targeting – Molecular Cell, 2020 Anticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance – PNAS, 2015 Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer – Cancer Research, 2004 Small heat shock proteins HSP27 (HspB1), αB-crystallin (HspB5) and HSP22 (HspB8) as regulators of cell death – International Journal of Biochemistry & Cell Biology, 2012
Gerassimos Pangalis | Haematology | Research Excellence Award Published on 08/04/202608/04/2026 by Top Pharmaceutical Prof. Gerassimos Pangalis | Haematology | Research Excellence Award Professor | Athens Medical Center |Greece Prof. Gerassimos Pangalis is a distinguished hematologist at Athens Medical Center, Psychikon Branch, Greece, recognized for his expertise in hematologic malignancies and clinical research. He earned advanced medical degrees with specialization in internal medicine and hematology, followed by extensive academic training in diagnostic and therapeutic hematology. Over his career, he has held senior clinical and academic positions, leading multidisciplinary teams and contributing to the development of innovative treatment protocols and translational research initiatives. His research focuses on lymphoproliferative disorders, particularly chronic lymphocytic leukemia and related malignancies, with numerous high-impact publications that have significantly influenced clinical practice and patient management strategies. Prof. Pangalis has also played key roles in collaborative research networks and clinical trials, advancing evidence-based hematology. He serves on editorial boards of reputable scientific journals and is an active member of leading professional organizations in hematology and oncology. His contributions have been recognized through multiple prestigious awards and honors, reflecting his commitment to advancing research, education, and excellence in clinical care. Citation Metrics (Google Scholar) 10761 8000 5000 2000 0 10761 154 52 Citations i10-index h-index View Google Scholar Profile Top 5 Featured Publications Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia – Seminars in Oncology, 2003 Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia – Journal of Clinical Oncology, 1997 Malignant lymphoma, well differentiated lymphocytic: its relationship with chronic lymphocytic leukemia and macroglobulinemia of Waldenström – Cancer, 1978 Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients – Haematologica, 2002 Senescence and senotherapeutics: a new field in cancer therapy – Seminars in Oncology, 1993
Gul Wali Khan | Medicinal Chemistry | Research Excellence Award Published on 08/04/2026 by Top Pharmaceutical Mr. Gul Wali Khan | Medicinal Chemistry | Research Excellence Award Research Assistant | Vorozhtsov Novosibirsk Institute of Organic Chemistry | Pakistan Mr. Gul Wali Khan is a Research Assistant in organic chemistry at the Novosibirsk Institute of Organic Chemistry, specializing in organometallic synthesis and characterization. He holds advanced degrees in chemistry with a strong focus on organic and coordination chemistry, including research on ferrocene-based bimetallic complexes and ligand design. His professional experience includes extensive laboratory research involving experimental design, spectroscopic characterization, data analysis, and collaborative scientific reporting, alongside prior academic roles in teaching and mentoring chemistry students. His research focuses on the synthesis, structural analysis, and biological evaluation of metal-based complexes, contributing to the advancement of organometallic chemistry with applications in antimicrobial studies and material science. He has authored peer-reviewed publications in reputable journals and is actively engaged in ongoing research projects, demonstrating consistent scholarly output. His contributions reflect a commitment to high-quality research, interdisciplinary collaboration, and growing academic impact, positioning him as a promising candidate for recognition in research excellence. Citation Metrics (Google Scholar) 11 8 5 2 0 1 1 1 Citations Documents h-index View Scopus Profile Featured Publications Synthesis, Characterization and Antimicrobial Activity of Ferrocene-Based Bimetallic Zn(II) Complexes with Mixed Ligands Containing 2,2′-Bipyridyl and 1,10-Phenanthroline – Journal of Organometallic Chemistry, 2025 (1 Citation)
Naglaa Shehab| Drug Discovery and Development | Research Excellence Award Published on 08/04/202608/04/2026 by Top Pharmaceutical Prof. Dr. Naglaa Shehab| Drug Discovery and Development | Research Excellence Award Professor | Dubai Medical University | United Arab Emirates Prof. Naglaa Gamil Shehab is a Professor of Pharmaceutical Sciences at Dubai Medical University, specializing in pharmacognosy, phytochemistry, medicinal plants, and complementary medicine. She holds advanced degrees in pharmacognosy with a strong foundation in phytochemical research and natural product analysis. Her academic career spans progressive roles from teaching and research to senior professorship and academic leadership, including key responsibilities in curriculum development and coordination of multidisciplinary pharmaceutical courses. Her research focuses on the pharmacognostical and phytochemical investigation of medicinal plants, contributing to the validation of natural therapies and alternative medicine through scientific methodologies. With a notable citation record, consistent publication output, and measurable scholarly impact, she has established herself as a recognized contributor to pharmaceutical sciences. She is actively engaged in academic service through editorial contributions, professional memberships, and mentorship of emerging researchers, reflecting sustained commitment to advancing research quality and innovation in pharmacognosy and related disciplines. Citation Metrics (Google Scholar) 779 600 400 200 0 779 18 14 Citations i10-index h-index View Scopus Profile View Google Scholar Profile Top 5 Featured Publications Impact of phenolic composition on hepatoprotective and antioxidant effects of four desert medicinal plants – BMC Complementary Medicine and Therapies Metabolic and biotransformation effects on dietary glucosinolates, their bioavailability and biological effects – Biotechnology Advances Antihyperuricemic and xanthine oxidase inhibitory activities of Tribulus arabicus and ursolic acid – PLOS ONE Therapeutic potentials of Crataegus azarolus leaves and its isolated compounds – BMC Complementary Medicine and Therapies Phenolic profiling and evaluation of contraceptive effect of Salsola imbricata extract – Evidence-Based Complementary and Alternative Medicine
Chrysoula Boutari | Cardiovascular Pharmacology | Research Excellence Award Published on 08/04/2026 by Top Pharmaceutical Assist. Prof. Dr. Chrysoula Boutari | Cardiovascular Pharmacology | Research Excellence Award Aristotle University of Thessaloniki | Greece Assist. Prof. Dr. Chrysoula Boutari is an Assistant Professor and Registrar of Internal Medicine at Hippokration General Hospital of Thessaloniki, Aristotle University of Thessaloniki, specializing in metabolic and cardiovascular disorders. She holds a medical degree with specialization in Internal Medicine and advanced research training through a fellowship at Beth Israel Deaconess Medical Center, Harvard Medical School, where she contributed to clinical and experimental medicine initiatives. Her professional experience includes leadership in multiple research and consultancy projects, with a strong focus on metabolic syndrome, obesity, MASLD, and dyslipidemias. She has produced a significant body of scholarly work with a high citation impact and h-index, alongside contributions to academic literature including books on cardiovascular iatrogenicity. She serves as Associate Editor and Guest Editor for reputable international journals, reflecting her influence in scientific publishing. Her professional affiliations include prominent atherosclerosis societies, highlighting her engagement with the global research community and continued commitment to advancing metabolic health research. Citation Metrics (Google Scholar) 2735 2000 1000 500 0 2735 72 24 Citations Documents h-index View Scopus Profile View ORCID Profile Top 5 Featured Publications HDL cholesterol as an associate of prevalent coronary artery disease in heterozygous familial hypercholesterolemia beyond LDL cholesterol – Endocrine Exploring the correlation between triglyceride levels and atherosclerotic cardiovascular disease prevalence in adults with familial hypercholesterolemia – Journal of Clinical Lipidology The effect of lipid-lowering treatment on indices of MASLD in familial hypercholesterolemia patients – Clinical Nutrition Circulating total and H-specific GDF15 levels are elevated in subjects with MASLD – Cardiovascular Diabetology FGF21 Analogues and MASLD: A Summary of Preclinical and Clinical Data – Review Article
Mohammad Awlad Mohammad | Oncology Pharmaceuticals | Research Excellence Award Published on 08/04/2026 by Top Pharmaceutical Dr. Mohammad Awlad Mohammad | Oncology Pharmaceuticals | Research Excellence Award Al-Quds University | Palestine Dr. Mohammad Awlad Mohammad is a medical doctor and emerging researcher affiliated with the Faculty of Medicine at Al-Quds University, specializing in clinical medicine and translational research. He completed his medical degree with a strong academic record, complemented by advanced training in scientific writing, systematic reviews, and research ethics. His clinical experience includes surgical electives and pathology observerships, where he developed practical competencies in operative assistance, diagnostic workflows, and patient-centered care. Actively engaged in research, his work focuses on clinical case studies, oncology disparities, neurological therapeutics, and evidence-based analysis, contributing as both first and co-author to peer-reviewed publications, including studies on acute appendicitis atypical presentation and thoracic oncology disparities, alongside ongoing projects in multiple sclerosis and GLP-1 receptor agonists. He has demonstrated leadership through participation in research camps and academic collaborations, strengthening interdisciplinary inquiry. His certifications in Basic and Advanced Cardiac Life Support and research training programs reflect a commitment to clinical excellence and scientific integrity, positioning him as a promising contributor to advancing medical research and practice. View ORCID Profile Top Featured Publications Disparities in Thoracic Oncology Patients Acute Appendicitis Presented with Testicular Pain Only
Chao Song | Drug Discovery and Development | Pharmaceutical Excellence Award Published on 08/04/202608/04/2026 by Top Pharmaceutical Mr. Chao Song | Drug Discovery and Development | Pharmaceutical Excellence Award Guangxi Traditional Chinese Medical University | China Mr. Chao Song is a PhD researcher at Guangxi University of Traditional Chinese Medicine, specializing in pharmacology, molecular biology, and translational medicine. He holds advanced academic training in biomedical sciences with a focus on traditional Chinese medicine and intervertebral disc disorders. His professional experience includes active participation in multiple provincial and municipal research projects, demonstrating strong collaborative and leadership capabilities in scientific investigations. His research primarily explores intervertebral disc degeneration, immune regulation, cellular senescence, and multi-omics integration, with contributions spanning network pharmacology, metabolomics, and metagenomics. He has authored numerous high-impact SCI publications, including first-author and corresponding-author works in leading journals, reflecting significant influence in his field. His technical expertise includes advanced experimental and analytical methods such as molecular assays, cell and animal studies, and scientific data visualization. His scholarly contributions have been recognized through competitive research funding, patent development, and consistent publication in high-impact journals, underscoring his growing reputation and commitment to advancing pharmaceutical and biomedical research. Citation Metrics (Google Scholar) 643 480 320 160 0 643 50 11 Citations Documents h-index View Scopus Profile Top 5 Featured Publications Mitochondrial Dysfunction: A New Molecular Mechanism of Intervertebral Disc Degeneration – Inflammation Research Cellular Senescence: Molecular Mechanisms of Intervertebral Disc Degeneration from an Immune Perspective – Biomedicine & Pharmacotherapy An In-Depth Analysis of the Immunomodulatory Mechanisms of Intervertebral Disc Degeneration – JOR Spine Bioinformatics-Based Discovery of Intervertebral Disc Degeneration Biomarkers and Immune-Inflammatory Infiltrates – JOR Spine Cellular Senescence and Immune Regulation in Intervertebral Disc Degeneration – PubMed Indexed Article
Shanshan Guo | Pharmacology | Research Excellence Award Published on 08/04/2026 by Top Pharmaceutical Dr. Shanshan Guo | Pharmacology | Research Excellence Award Principal Investigator | China Academy of Chinese Medical Sciences | China Dr. Shanshan Guo is a Principal Investigator and Director at the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, specializing in pharmacology and integrative medicine with a focus on Chinese materia medica and respiratory diseases. She holds advanced degrees in traditional Chinese medicine, integrated Chinese and Western medicine, and pharmacology, reflecting a strong interdisciplinary academic foundation. Her professional career demonstrates progressive leadership, including roles as Principal Investigator and research lead, where she has directed major pharmacological research initiatives and innovative experimental platforms. Her research centers on antiviral therapeutics, mechanisms of pathogen-host interaction, and safety evaluation of traditional Chinese medicine, supported by extensive publications and impactful contributions to translational medicine. She has successfully led funded projects on broad-spectrum antiviral agents and pharmacodynamic mechanisms of herbal formulations, highlighting her scientific rigor and innovation. Dr. Guo’s work has earned recognition through competitive research funding, leadership responsibilities, and contributions to advancing evidence-based integration of traditional and modern medicine, positioning her as a significant contributor to global pharmaceutical and biomedical research. Citation Metrics (Google Scholar) 745 560 375 190 0 745 116 15 Citations Documents h-index View Scopus Profile Top 5 Featured Publications Attenuate Host Susceptibility to Respiratory Virus Invasion by Inhibiting Interactions Between Host Proteins SLC16A3 and AP1G1 – Microbiology Spectrum Verbenalin Protects Against Coronavirus Pneumonia by Promoting Host Immune Homeostasis – Phytomedicine An advanced network pharmacology investigation of Shufeng Jiedu formula in the treatment for respiratory tract infection based on LC–MS, data mining, molecular docking, and molecular dynamic simulation – Frontiers / Open Access Platform Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice – Pharmacological Review Pharmacological effects and mechanisms of Xuanfei Baidu Decoction in the treatment of viral pneumonia – Chinese Journal of Pharmacovigilance